Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data
Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data is a paper indexed in PICO Portal from OpenAlex.
How many citations does Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data have?
Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data has 0 citations in the OpenAlex counts PICO Portal stores.
When was Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data published?
Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data has 2026 year in the PICO Portal index.
What is the open-access status of Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data?
Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data has hybrid oa status in the PICO Portal index.
What is the DOI of Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data?
The DOI for Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data is on the source record.
What is the PMID of Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data?
The PMID for Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data is on the source record.
What is the OpenAlex record for Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data?
The OpenAlex for Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( <scp>RISE</scp> ‐ <scp>AMD</scp> ): Safety data is on the source record.